Pathogenesis and Management of Graft-versus-Host Disease

Immunology and Allergy Clinics of North America

Volumn 30, Issue 1, 2010, Pages 75-101

  Choi, Sung W ^a   Levine, John E ^a   Ferrara, James L M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Acute graft versus host disease; Chronic graft versus host disease; GVHD; Hematopoietic cell transplantation

Indexed keywords

ALEFACEPT; ALEMTUZUMAB; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DENILEUKIN DIFTITOX; ETANERCEPT; GAMMA INTERFERON; IMATINIB; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLIN G; PENTOSTATIN; PLACEBO; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CHEMOPROPHYLAXIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOMAGNESEMIA; INFECTION; INFLAMMATION; LIVER DISEASE; LOW DRUG DOSE; MESENCHYMAL STEM CELL; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PUVA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SKIN DISEASE; STREPTOCOCCUS INFECTION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION;

ANIMALS; CHEMOKINES; CYTOKINES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA; MICE; RISK FACTORS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 74949111776     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2009.10.001     Document Type: Review

References (155)

1. Ferrara J.L., and Deeg H.J. Graft-versus-host disease. N Engl J Med 324 10 (1991) 667-674
2. Welniak L.A., Blazar B.R., and Murphy W.J. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 25 (2007) 139-170
3. Reddy P., Arora M., Guimond M., et al. GVHD: a continuing barrier to the safety of allogeneic transplantation. Biol Blood Marrow Transplant 15 Suppl 1 (2008) 162-168
4. Billingham R.E. The biology of graft-versus-host reactions. Harvey Lect 62 (1966) 21-78
5. Korngold R., and Sprent J. Purified T cell subsets and lethal graft-versus-host disease in mice. In: Gale R.P., and Champlin R. (Eds). Progress in bone marrow transplant (1987), Alan R. Liss, Inc, New York 213-218
6. Kernan N.A., Collins N.H., Juliano L.L., et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 68 3 (1986) 770-773
7. Erlich H.A., Opelz G., and Hansen J. HLA DNA typing and transplantation. Immunity 14 4 (2001) 347-356
8. Loiseau P., Busson M., Balere M.L., et al. HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant 13 8 (2007) 965-974
9. Hahn T., McCarthy Jr. P.L., Zhang M.J., et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 26 35 (2008) 5728-5734
10. Kernan N.A., Bartsch G., Ash R.C., et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328 9 (1993) 593-602
11. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104 7 (2004) 1923-1930
12. Bray R.A., Hurley C.K., Kamani N.R., et al. National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol Blood Marrow Transplant 14 Suppl 9 (2008) 45-53
13. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110 13 (2007) 4576-4583
14. Goulmy E., Schipper R., Pool J., et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 334 5 (1996) 281-285
15. Bleakley M., and Riddell S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 4 5 (2004) 371-380
16. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 157 (1997) 125-140
17. Antin J.H., and Ferrara J.L. Cytokine dysregulation and acute graft-versus-host disease. Blood 80 12 (1992) 2964-2968
18. Cavet J., Middleton P.G., Segall M., et al. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 94 11 (1999) 3941-3946
19. Lin M.T., Storer B., Martin P.J., et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349 23 (2003) 2201-2210
20. Dickinson A.M., and Charron D. Non-HLA immunogenetics in hematopoietic stem cell transplantation. Curr Opin Immunol 17 5 (2005) 517-525
21. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 8 (2005) 3051-3057
22. Miller J.S., Cooley S., Parham P., et al. Missing KIR-ligands is associated with less relapse and increased graft versus host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109 11 (2007) 5058-5061
23. Velardi A., Ruggeri L., Alessandro, et al. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol 23 9 (2002) 438-444
24. Holler E., Rogler G., Brenmoehl J., et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 107 10 (2006) 4189-4193
25. Weisdorf D., Hakke R., Blazar B., et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 51 6 (1991) 1197-1203
26. Eisner M.D., and August C.S. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 15 5 (1995) 663-668
27. Martin P., Bleyzac N., Souillet G., et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 32 9 (2003) 881-887
28. Gale R.P., Bortin M.M., van Bekkum D.W., et al. Risk factors for acute graft-versus-host disease. Br J Haematol 67 4 (1987) 397-406
29. Nash R.A., Pepe M.S., Storb R., et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 80 7 (1992) 1838-1845
30. Vigorito A.C., Azevedo W.M., Marques J.F., et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 22 12 (1998) 1145-1151
31. Cutler C., Giri S., Jeyapalan S., et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 19 16 (2001) 3685-3691
32. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 369 9577 (2007) 1947-1954
33. Kurtzberg J., Laughlin M., Graham M.L., et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 335 3 (1996) 157-166
34. Gluckman E., Rocha V., Boyer-Chammard A., et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 337 6 (1997) 373-381
35. Laughlin M.J., Barker J., Bambach B., et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 344 24 (2001) 1815-1822
36. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100 5 (2002) 1611-1618
37. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351 22 (2004) 2276-2285
38. Grewal S.S., Barker J.N., Davies S.M., et al. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?. Blood 101 11 (2003) 4233-4244
39. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 3 (2005) 1343-1347
40. Macmillan M.L., Weisdorf D.J., Brunstein C.G., et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 113 11 (2009) 2410-2415
41. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314 12 (1986) 729-735
42. Hiraoka A., Ohashi Y., Okamoto S., et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 28 2 (2001) 181-185
43. Horowitz M.M., Przepiorka D., Bartels P., et al. Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. Biol Blood Marrow Transplant 5 3 (1999) 180-186
44. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92 7 (1998) 2303-2314
45. Ram R., Gafter-Gvili A., Yeshurun M., et al. Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 43 8 (2009) 643-653
46. Nash R.A., Antin J.H., Karanes C., et al. Phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96 6 (2000) 2062-2068
47. van Hooff J.P., Squifflet J.P., Wlodarczyk Z., et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 75 12 (2003) 1934-1939
48. Kirken R.A., and Wang Y.L. Molecular actions of sirolimus: sirolimus and mTor. Transplant Proc 35 Suppl 3 (2003) 227S-230S
49. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 109 7 (2007) 3108-3114
50. Bolwell B., Sobecks R., Pohlman B., et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 34 7 (2004) 621-625
51. Bornhauser M., Schuler U., Porksen G., et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 67 4 (1999) 499-504
52. Kasper C., Sayer H.G., Mugge L.O., et al. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant 33 1 (2004) 65-69
53. Mohty M., de Lavallade H., Faucher C., et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 34 6 (2004) 527-530
54. Vogelsang G.B., and Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 27 12 (2001) 1255-1262
55. Niederwieser D., Maris M., Shizuru J.A., et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101 4 (2003) 1620-1629
56. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78 8 (1991) 2120-2130
57. Martin P.J., Hansen J.A., Torok-Storb B., et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 3 5 (1988) 445-456
58. O'Reilly R.J. T-cell depletion and allogeneic bone marrow transplantation. Semin Hematol 29 2 Suppl 1 (1992) 20-26
59. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96 7 (2000) 2419-2425
60. Barge R.M.Y., Starrenburg C.W.J., Falkenburg J.H.F., et al. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience. Bone Marrow Transplant 37 12 (2006) 1129-1134
61. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 10 (2001) 2942-2947
62. Reddy P., and Ferrara J.L. Immunobiology of acute graft-versus-host disease. Blood Rev 17 4 (2003) 187-194
63. Hill G.R., and Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95 9 (2000) 2754-2759
64. Xun C.Q., Thompson J.S., Jennings C.D., et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83 8 (1994) 2360-2367
65. Couriel D.R., Saliba R.M., Giralt S., et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 10 3 (2004) 178-185
66. Choi S.W., Kitko C.L., Braun T., et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 112 4 (2008) 1539-1542
67. Matzinger P. The danger model: a renewed sense of self. Science 296 5566 (2002) 301-305
68. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 5426 (1999) 412-415
69. Murai M., Yoneyama H., Ezaki T., et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 4 2 (2003) 154-160
70. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 8 6 (2002) 575-581
71. Reddy P., Maeda Y., Liu C., et al. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 11 11 (2005) 1244-1249
72. Duffner U.A., Maeda Y., Cooke K.R., et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 172 12 (2004) 7393-7398
73. Maeda Y., Reddy P., Lowler K.P., et al. Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. Blood 106 2 (2005) 749-755
74. Merad M., Hoffmann P., Ranheim E., et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 10 5 (2004) 510-517
75. Nachbaur D., Kircher B., Eisendle K., et al. Phenotype, function and chimaerism of monocyte-derived blood dendritic cells after allogeneic haematopoietic stem cell transplantation. Br J Haematol 123 1 (2003) 119-126
76. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 104 4 (2004) 961-968
77. Korngold R., and Sprent J. Negative selection of T cells causing lethal graft-versus-host disease across minor histocompatibility barriers. Role of the H-2 complex. J Exp Med 151 5 (1980) 1114-1124
78. Beilhack A., Schulz S., Baker J., et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 106 3 (2005) 1113-1122
79. Kloosterman T.C., Tielemans M.J., Martens A.C., et al. Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia. Bone Marrow Transplant 14 1 (1994) 15-22
80. Weijtens M., van Spronsen A., Hagenbeek A., et al. Reduced graft-versus-host disease-inducing capacity of T cells after activation, culturing, and magnetic cell sorting selection in an allogeneic bone marrow transplantation model in rats. Hum Gene Ther 13 2 (2002) 187-198
81. Cobbold S., Martin G., and Waldmann H. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo. Transplantation 42 3 (1986) 239-247
82. Sun Y., Tawara I., Toubai T., et al. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res 150 4 (2007) 197-214
83. Greenwald R.J., Freeman G.J., and Sharpe A.H. The B7 family revisited. Annu Rev Immunol 23 (2005) 515-548
84. Cohen J.L., and Boyer O. The role of CD4+CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease. Curr Opin Immunol 18 5 (2006) 580-585
85. Stanzani M., Martins S.L., Saliba R.M., et al. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk of graft-versus-host disease following HLA-identical stem cell transplantation in humans. Blood 103 3 (2003) 1140-1146
86. Rezvani K., Mielke S., Ahmadzadeh M., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108 4 (2006) 1291-1297
87. Ziegler S.F. FOXP3: of mice and men. Annu Rev Immunol 24 (2006) 209-226
88. Ferrara J.L., and Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 43 1 (2006) 3-10
89. Rolink A.G., and Gleichmann E. Allosuppressor- and allohelper-T cells in acute and chronic graft-vs.-host (GVH) disease. III. Different Lyt subsets of donor T cells induce different pathological syndromes. J Exp Med 158 2 (1983) 546-558
90. Zeiser R., Nguyen V.H., Beilhack A., et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108 1 (2006) 390-399
91. Krenger W., Falzarano G., Delmonte Jr. J., et al. Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood 88 3 (1996) 1113-1121
92. Yang Y.G., Dey B.R., Sergio J.J., et al. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest 102 12 (1998) 2126-2135
93. Moore K.W., de Waal Malefyt R., Coffman R.L., et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19 (2001) 683-765
94. Lin M.T., Storer B., Martin P.J., et al. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. Blood 106 12 (2005) 3995-4001
95. Holler E., Roncarolo M.G., Hintermeier-Knabe R., et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 25 3 (2000) 237-241
96. Banovic T., MacDonald K.P., Morris E.S., et al. TGF-beta in allogeneic stem cell transplantation: friend or foe?. Blood 106 6 (2005) 2206-2214
97. van den Brink M.R., and Burakoff S.J. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2 4 (2002) 273-281
98. Wysocki C.A., Panoskaltsis-Mortari A., Blazar B.R., et al. Leukocyte migration and graft-versus-host disease. Blood 105 11 (2005) 4191-4199
99. Pribila J.T., Quale A.C., Mueller K.L., et al. Integrins and T cell-mediated immunity. Annu Rev Immunol 22 (2004) 157-180
100. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 10 (2004) 987-995
101. Abhyankar S., Gilliland D.G., and Ferrara J.L. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation 56 6 (1993) 1518-1523
102. Tanaka J., Imamura M., Kasai M., et al. Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 85 3 (1993) 558-565
103. Antin J.H., Weisdorf D., Neuberg D., et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100 10 (2002) 3479-3482
104. Martin P., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76 8 (1990) 1464-1472
105. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11 12 (2005) 945-956
106. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 6 (1995) 825-828
107. Cahn J.Y., Klein J.P., Lee S.J., et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 106 4 (2005) 1495-1500
108. Vogelsang G.B., Lee L., and Bensen-Kennedy D.M. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 54 (2003) 29-52
109. Goker H., Haznedaroglu I.C., and Chao N.J. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 29 3 (2001) 259-277
110. Choi S.W., Islam S., Greenson J.K., et al. The use of laparoscopic liver biopsies in pediatric patients with hepatic dysfunction following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 36 10 (2005) 891-896
111. Snover D.C., Weisdorf S.A., Ramsay N.K., et al. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology 4 1 (1984) 123-130
112. Nevo S., Enger C., Swan V., et al. Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival. Transplantation 67 5 (1999) 681-689
113. Snover D.C., Weisdorf S.A., Vercellotti G.M., et al. A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol 16 4 (1985) 387-392
114. Paczesny S., Levine J.E., Braun T.M., et al. Plasma biomarkers in graft-versus-host disease: a new era?. Biol Blood Marrow Transplant 15 Suppl 1 (2008) 33-38
115. Paczesny S., Krijanovski O.I., Braun T.M., et al. A biomarker panel for acute graft-versus-host disease. Blood 113 2 (2009) 273-278
116. Weisdorf D., Haake R., Blazar B., et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75 4 (1990) 1024-1030
117. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 8 7 (2002) 387-394
118. Bertz H., Afting M., Kreisel W., et al. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant 24 11 (1999) 1185-1189
119. Hockenbery D.M., Cruickshank S., Rodell T.C., et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 109 10 (2007) 4557-4563
120. Shapira M.Y., Bloom A.I., Or R., et al. Intra-arterial catheter directed therapy for severe graft-versus-host disease. Br J Haematol 119 3 (2002) 760-764
121. Deeg H.J. How I treat refractory acute GVHD. Blood 109 10 (2007) 4119-4126
122. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft vs. host disease: a randomized phase II trial from the BMT CTN. Blood 114 (2009) 511-517
123. Lamioni A., Parisi F., Isacchi G., et al. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 79 7 (2005) 846-850
124. Gatza E., Rogers C.E., Clouthier S.G., et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 112 4 (2008) 1515-1521
125. Greinix H.T., Knobler R.M., Worel N., et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 91 3 (2006) 405-408
126. Perfetti P., Carlier P., Strada P., et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 42 9 (2008) 609-617
127. Calore E., Calo A., Tridello G., et al. Extracorporeal photochemotherapy may improve outcome in children with acute GVHD. Bone Marrow Transplant 42 6 (2008) 421-425
128. Berger M., Pessolano R., Albiani R., et al. Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report. J Pediatr Hematol Oncol 29 10 (2007) 678-687
129. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 10 (2006) 1390-1397
130. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 9624 (2008) 1579-1586
131. Socie G., Stone J.V., Wingard J.R., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 341 1 (1999) 14-21
132. Lee S.J., Vogelsang G., and Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 9 4 (2003) 215-233
133. Weiden P.L., Flournoy N., Sanders J.E., et al. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc 13 1 Pt 1 (1981) 248-251
134. Lee S.J., Klein J.P., Barrett A.J., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 100 2 (2002) 406-414
135. Pavletic S.Z., Smith L.M., Bishop M.R., et al. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol 78 4 (2005) 265-274
136. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 2 (1980) 204-217
137. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 12 4 (2006) 375-396
138. Martin P.J., Storer B.E., Rowley S.D., et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 113 21 (2009) 5074-5082
139. Zaja F., Bacigalupo A., Patriarca F., et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 40 3 (2007) 273-277
140. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108 2 (2006) 756-762
141. Svegliati S., Olivieri A., Campelli N., et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110 1 (2007) 237-241
142. Olivieri A., Locatelli F., Zecca M., et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 114 3 (2009) 709-718
143. Rizzo J.D., Curtis R.E., Socie G., et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113 5 (2009) 1175-1183
144. Kumar A., Teuber S.S., and Gershwin M.E. Intravenous immunoglobulin: striving for appropriate use. Int Arch Allergy Immunol 140 3 (2006) 185-198
145. Kulkarni S., Powles R., Treleaven J., et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 95 12 (2000) 3683-3686
146. Ho V.T., Zahrieh D., Hockenberg D., et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft versus host disease after allogeneic hemutopoietic stem cell transplantation. Blood 104 4 (2004) 1224-1226
147. Shaughnessy P.J., Bachier C., Grimley M., et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 11 3 (2005) 188-193
148. Levine J.E., Paczesny S., Mineishi S., et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 111 4 (2008) 2470-2475
149. Bolanos-Meade J., Jacobsohn D.A., Margolis J., et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 23 12 (2005) 2661-2668
150. Basara N., Kiehl M.G., Blau W., et al. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc 33 3 (2001) 2121-2123
151. Krejci M., Doubek M., Buchler T., et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 84 10 (2005) 681-685
152. Takami A., Mochizuki K., Okumura H., et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol 83 1 (2006) 80-85
153. Benito A.I., Furlong T., Martin P.J., et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72 12 (2001) 1924-1929
154. von Bonin M., Stolzel F., Goedecke A., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 43 3 (2009) 245-251
155. Shapira M.Y., Resnick I.B., Bitan M., et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant 36 12 (2005) 1097-1101